ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

ravulizumab

Also written as “Ravulizumab”, “ALXN1210” and “ALXN1210 SC”.

Its studies are mostly in Hemoglobinuria, Paroxysmal · Myasthenia Gravis · Thrombotic Microangiopathies · Neuromyelitis Optica · Atypical Hemolytic Uremic Syndrome, led by 2 companies.

Drug pageRavulizumab: every studyAll 39 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 4, since Mar 23, 202035 company-led studies, 9 open or runningNext primary completion: Jun 25, 2027 (phase 4)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
AstraZeneca349 open or runningphase 4since Mar 23, 2020Nov 2, 2015Jun 25, 2027phase 4 · NCT07308574
Regeneron Pharmaceuticalsits history only10 open or runningphase 3since Nov 12, 2021Nov 12, 2021none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of AstraZeneca only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

Not listed one by one: 17 earlier studies, Nov 2, 2015 to Jan 28, 2021.

  1. Jun 9, 2017Named ravulizumabINNProposed as its International Nonproprietary Name in WHO's List 117 · before, ALXN1210
  2. Aug 4, 2021Phase 3 study in DermatomyositisNCT04999020 · 38 enrolled · United States, Australia, Brazil and more
  3. Mar 11, 20224 phase 1 studies in HealthyNCT05288829, NCT05288816, NCT05288673 and 1 more
  4. Apr 20, 2022Phase 3 study in Neuromyelitis OpticaNCT05346354 · 12 enrolled · United States, Canada, France and more
  5. May 25, 2022Phase 1 study in HealthyNCT05396742 · 49 enrolled · United Kingdom
  6. Dec 1, 2022Phase 3 study in Myasthenia GravisNCT05644561 · 12 enrolled · United States, Italy, Japan and more
  7. Feb 16, 2023Phase 3 study in Renal Insufficiency, ChronicNCT05746559 · 555 enrolled · United States, Argentina, Australia and more
  8. Feb 26, 2024Phase 3 study in Glomerulonephritis, IGANCT06291376 · 584 enrolled · United States, Argentina, Australia and more
  9. Aug 28, 2024Phase 3 study in Hemoglobinuria, ParoxysmalNCT06578949 · 18 enrolled · China
  10. Feb 10, 2025Phase 3 study in Delayed Graft FunctionNCT06830798 · 450 planned · United States, Argentina, Australia and more
  11. Jun 9, 2025Phase 3 study in Glomerulonephritis, IGANCT07024563 · 36 planned · United States, China, Italy and more
  12. Oct 3, 2025Phase 4 study in Myasthenia GravisNCT07221838 · 75 planned · United States, Germany, Italy and more
  13. Dec 17, 2025Phase 4 study in Atypical Hemolytic Uremic SyndromeNCT07308574 · 20 planned · Japan
  14. Apr 23, 2026Phase 3 study in Neuromyelitis OpticaNCT07557420 · 19 planned · China
  15. May 13, 2026Phase 3 study in Myasthenia GravisNCT07596784 · 20 planned · China

Ahead

  1. Jun 25, 2027Primary completion: phase 4 study in Atypical Hemolytic Uremic SyndromeNCT07308574
  2. Aug 24, 2027Primary completion: phase 3 study in Myasthenia GravisNCT07596784
  3. Aug 27, 2027Primary completion: phase 4 study in Myasthenia GravisNCT07221838
  4. Nov 30, 2027Primary completion: phase 3 study in Delayed Graft FunctionNCT06830798

TargetBeta

C5 →read by rule
“Complement C5 inhibitor”ChEMBL 37, by rule

Other programs on C5

ProgramCompanyFurthest phaseStudies
eculizumabruleAstraZenecaphase 438
pozelimabruleRegeneron Pharmaceuticalsphase 414
zilucoplanruleUCBphase 314
vilobelimabruleinflarx-gmbhphase 313
CrovalimabruleHoffmann-La Rochephase 310
cemdisiranruleRegeneron Pharmaceuticalsphase 310
ABBV-6628AbbViephase 21

Studies

All 34 AstraZeneca leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07596784Myasthenia Gravis · China3RecruitingAug 24, 202720
NCT07557420Neuromyelitis Optica · China3RecruitingSep 19, 202819
NCT07308574Atypical Hemolytic Uremic Syndrome · Japan4RecruitingJun 25, 202720
NCT07221838Myasthenia Gravis · United States, Germany, Italy and more4RecruitingAug 27, 202775
NCT07024563Glomerulonephritis, IGA · United States, China, Italy and more3RecruitingNov 29, 202836
NCT06830798Delayed Graft Function · United States, Argentina, Australia and more3RecruitingNov 30, 2027450
NCT06578949Hemoglobinuria, Paroxysmal · China3CompletedMay 15, 202518
NCT06291376Glomerulonephritis, IGA · United States, Argentina, Australia and more3Active, not recruitingJan 5, 2026584
NCT05746559Renal Insufficiency, Chronic · United States, Argentina, Australia and more3TerminatedOct 7, 2025555
NCT05644561Myasthenia Gravis · United States, Italy, Japan and more3Active, not recruitingJul 15, 202612
NCT05396742Healthy · United Kingdom1CompletedMay 21, 201949
NCT05346354Neuromyelitis Optica · United States, Canada, France and more3Active, not recruitingJun 22, 202612
NCT05288829Healthy · United Kingdom1CompletedJul 18, 201742
NCT05288816Healthy · United Kingdom1CompletedJul 5, 201716
NCT05288673Healthy · United Kingdom1CompletedSep 1, 201616
NCT05288660Healthy · Canada1CompletedMar 13, 201514
NCT04999020Dermatomyositis · United States, Australia, Brazil and more3TerminatedOct 26, 202338
NCT04743804Thrombotic Microangiopathies · United States, Belgium, Brazil and more3TerminatedDec 22, 202216
NCT04564339Lupus Nephritis · United States, Australia, Canada and more2TerminatedMar 26, 2025123
NCT04557735Thrombotic Microangiopathies · United States, Israel, Italy and more3CompletedNov 26, 202441
NCT04543591Thrombotic Microangiopathies · United States, Australia, Belgium and more3CompletedSep 19, 2025148
NCT04369469Acute Lung Injury · United States, France, Japan and more3TerminatedFeb 8, 2021202
NCT04320602Hemoglobinuria, Paroxysmal · United Kingdom4CompletedDec 20, 202218
NCT04248465Amyotrophic Lateral Sclerosis · United States, Australia, Belgium and more3TerminatedOct 17, 2021382
NCT04201262Neuromyelitis Optica · United States, Australia, Austria and more3CompletedMar 15, 202258
NCT03920293Myasthenia Gravis · United States, Austria, Canada and more3CompletedMay 11, 2021175
NCT03748823Hemoglobinuria, Paroxysmal · United States, Australia, Austria and more3CompletedFeb 2, 2021139
NCT03406507Hemoglobinuria, Paroxysmal · United States, France, Netherlands and more3CompletedMar 25, 202013
NCT03131219Atypical Hemolytic Uremic Syndrome · United States, Belgium, Germany and more3CompletedDec 20, 202234
NCT03056040Hemoglobinuria, Paroxysmal · United States, Australia, Canada and more3CompletedFeb 21, 2022202
NCT02949128Atypical Hemolytic Uremic Syndrome · United States, Australia, Austria and more3CompletedJan 24, 202358
NCT02946463Hemoglobinuria, Paroxysmal · United States, Argentina, Australia and more3CompletedFeb 28, 2023272
NCT02605993Hemoglobinuria, Paroxysmal · Canada, France, Germany and more2CompletedFeb 23, 201726
NCT02598583Hemoglobinuria, Paroxysmal · Australia, Korea, Republic of2CompletedJul 14, 201613

How it is read

Names in the registry

  • “Ravulizumab”, 30 entries
  • “ALXN1210”, 4 entries
  • “ALXN1210 SC”, 1 entry
  • “ALXN1210 IV”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.